Investors & Media

Transformative science, targeted medicines

We are working to advance a deep pipeline of precision therapies, designed to allow patients to live longer, better lives. Our approach combines world-leading expertise in protein kinases with sound execution and an intense focus on discovery.

News release details

Blueprint Medicines to Present at 16th Annual Morgan Stanley Global Healthcare Conference

September 5, 2018 at 8:00 AM EDT

CAMBRIDGE, Mass., Sept. 5, 2018 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a leader in discovering and developing targeted kinase medicines for patients with genomically defined diseases, today announced that company management will participate in a fireside chat at the 16th Annual Morgan Stanley Global Healthcare Conference on Wednesday, September 12, 2018 at 1:40 p.m. ET.

Print

A live webcast of the presentation will be available by visiting the Investors section of Blueprint Medicines' website at http://ir.blueprintmedicines.com. A replay of the webcast will be archived on Blueprint Medicines' website for 30 days following the presentation.

About Blueprint Medicines

Blueprint Medicines is developing a new generation of targeted and potent kinase medicines to improve the lives of patients with genomically defined diseases. Its approach is rooted in a deep understanding of the genetic blueprint of cancer and other disease driven by the abnormal activation of kinases. Blueprint Medicines is advancing multiple programs in clinical development for subsets of patients with gastrointestinal stromal tumors, hepatocellular carcinoma, systemic mastocytosis, non-small cell lung cancer, medullary thyroid cancer and other advanced solid tumors, as well as multiple programs in research and preclinical development. For more information, please visit www.blueprintmedicines.com.

Cision View original content with multimedia:http://www.prnewswire.com/news-releases/blueprint-medicines-to-present-at-16th-annual-morgan-stanley-global-healthcare-conference-300706667.html

SOURCE Blueprint Medicines

Investor and Media Relations Contacts, Kristin Hodous, 617-714-6674, KHodous@blueprintmedicines.com, Jim Baker, 617-844-8236, JBaker@blueprintmedicines.com